Target intelligence / Profile preview

Glucose transporter type 3 (GLUT3)

Target
GLUT3
Molecular classification
Transporter, Solute carrier family, Major facilitator superfamily (MFS)
01

Overview

Glucose transporter type 3 (GLUT3) is a high-affinity facilitative glucose transporter encoded by the SLC2A3 gene and is a member of the solute carrier family and the major facilitator superfamily (MFS)[5][6]. It is primarily expressed in neurons, where it maintains adequate glucose supply to support high metabolic activity, and is also found in sperm, placenta, and certain cancer cells[1][5][4]. GLUT3 proteins have twelve transmembrane segments, forming an integral membrane glycoprotein structure that enables the rapid and efficient translocation of glucose and related hexoses across the plasma membrane following the glucose concentration gradient[1][2]. It plays an essential role in neurodevelopment and function, and defects or dysregulation of GLUT3 are associated with neurodegenerative diseases, impaired fetal development, and are observed in hypoxia-adapted and some malignant tissues[4][1]. While no approved drugs selectively target GLUT3 for therapy, inhibitors like cytochalasin B serve as experimental tools to study its structure and function[2][7].

Other names
Facilitated glucose transporter member 3Solute carrier family 2 member 3SLC2A3Brain-type glucose transporter
02

Mechanism of action

Inhibition of glucose uptake through competitive binding at the transporter (as with cytochalasin B)

03

Biological functions

Glucose uptakeTransport of hexoses (e.g. glucose, galactose, mannose, xylose, fucose)Energy metabolismNeuronal glucose supply
04

Disease associations

Neurodegenerative diseaseCancerFetal development disordersHypoxia adaptationAlzheimer’s disease
05

Safety considerations

Potential for neurotoxicity or fetal impairment if over-inhibited due to its key role in neuronal and embryonic glucose supply
06

Interacting drugs

Cytochalasin B (GLUT inhibitor)

1 more in the full profile.

07

Biomarkers

Elevated GLUT3 expression (tissue biomarker in certain cancers and neurological disorders)

Beyond the preview

Go deeper on Glucose transporter type 3 (GLUT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glucose transporter type 3 (GLUT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call